title: Omeprazole Inhibits Pancreatic Cancer Cell Invasion through a Nongenomic Aryl Hydrocarbon Receptor Pathway.
abstract: Omeprazole and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) are aryl hydrocarbon receptor (AhR) agonists that inhibit the invasion of breast cancer cells through inhibition of CXCR4 transcription. Treatment of highly invasive Panc1 pancreatic cancer cells with TCDD, omeprazole, and seven other AhR-active pharmaceuticals showed that only omeprazole and tranilast, but not TCDD, inhibited invasion in a Boyden chamber assay. Similar results were observed in MiaPaCa2 cells, another quasimensenchymal pancreatic ductal adenocarcinoma (QM-PDA) pancreatic cancer cell line, whereas invasion was not observed with BxPC3 or L3.6pL cells, which are classified as classical (less invasive) pancreatic cancer cells. It was also observed in QM-PDA cells that TCDD, omeprazole, and tranilast did not induce CYP1A1 or CXCR4 and that treatment with these compounds did not result in nuclear uptake of AhR. In contrast, treatment of BxPC3 and L3.6pL cells with these AhR ligands resulted in induction of CYP1A1 (by TCDD) and nuclear uptake of AhR, which was similar to that observed for Ah-responsive MDA-MB-468 breast and HepG2 liver cancer cell lines. Results of AhR and AhR nuclear translocator (Arnt) knockdown experiments in Panc1 and MiaPaCa2 cells demonstrated that omeprazole- and tranilast-mediated inhibition of invasion was AhR-dependent but Arnt-independent. These results demonstrate that in the most highly invasive subtype of pancreatic cancer cells (QM-PDA) the selective AhR modulators omeprazole and tranilast inhibit invasion through a nongenomic AhR pathway.
authors.forename: Un-Ho
authors.initials: UH
authors.lastname: Jin
authors.affiliation: ‡Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, United States.
authors.forename: Sang-Bae
authors.initials: SB
authors.lastname: Kim
authors.forename: Stephen
authors.initials: S
authors.lastname: Safe
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D019363:Cytochrome P-450 CYP1A1 / Q000378:metabolism; D005260:Female; D006801:Humans; D009361:Neoplasm Invasiveness / Q000473:pathology / Q000517:prevention & control*; D009853:Omeprazole / Q000494:pharmacology*; D010179:Pancreas / Q000187:drug effects* / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018336:Receptors, Aryl Hydrocarbon / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D018336:Receptors, Aryl Hydrocarbon; D019363:Cytochrome P-450 CYP1A1; D009853:Omeprazole
references.citation: Science. 2010 Sep 10;329(5997):1345-8
references.pmid: 20688981
references.citation: Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13481-6
references.pmid: 19651607
references.citation: J Pharmacol Exp Ther. 2011 Jul;338(1):318-27
references.pmid: 21493753
references.citation: Gastroenterology. 2011 Jul;141(1):237-48, 248.e1
references.pmid: 21600206
references.citation: Mol Pharmacol. 2014 Apr;85(4):533-41
references.pmid: 24431146
references.citation: Nutr Rev. 2013 Jun;71(6):353-69
references.pmid: 23731446
references.citation: Toxicol Sci. 2013 Sep;135(1):1-16
references.pmid: 23771949
references.citation: Nature. 2011 Oct 05;478(7368):197-203
references.pmid: 21976023
references.citation: Nature. 2008 May 1;453(7191):65-71
references.pmid: 18362915
references.citation: J Biol Chem. 2001 Nov 9;276(45):41841-9
references.pmid: 11551926
references.citation: BMC Cancer. 2014 Jul 09;14:498
references.pmid: 25011475
references.citation: Cell. 2011 Oct 28;147(3):629-40
references.pmid: 21999944
references.citation: Mol Pharmacol. 2007 Jun;71(6):1475-86
references.pmid: 17327465
references.citation: Annu Rev Pharmacol Toxicol. 2000;40:519-61
references.pmid: 10836146
references.citation: Nat Med. 2011 Apr;17 (4):500-3
references.pmid: 21460848
references.citation: Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9990-5
references.pmid: 12107286
references.citation: Nature. 2008 May 1;453(7191):106-9
references.pmid: 18362914
references.citation: PLoS One. 2011;6(8):e23522
references.pmid: 21858153
references.citation: Nat Immunol. 2011 Nov 20;13(2):144-51
references.pmid: 22101730
references.citation: Mol Cancer Res. 2012 Oct;10 (10 ):1369-79
references.pmid: 22912337
references.citation: Oncogene. 2013 Apr 4;32(14):1811-20
references.pmid: 22665056
references.citation: Biochemistry. 2008 Dec 30;47(52):13997-4008
references.pmid: 19063610
references.citation: Oncogene. 2002 Sep 5;21(39):6059-70
references.pmid: 12203118
references.citation: Mol Pharmacol. 2011 Mar;79(3):508-19
references.pmid: 21127131
references.citation: Biol Chem. 2010 Oct;391(10 ):1205-19
references.pmid: 20707612
references.citation: Inflamm Bowel Dis. 2011 May;17(5):1149-62
references.pmid: 20878756
references.citation: Immunology. 2009 Jul;127(3):299-311
references.pmid: 19538249
references.citation: Biochem Pharmacol. 2009 Feb 15;77(4):746-60
references.pmid: 19100241
references.citation: J Pharmacol Exp Ther. 2012 Nov;343 (2):333-41
references.pmid: 22879383
references.citation: Biochem Pharmacol. 1996 Apr 26;51(8):1077-87
references.pmid: 8866830
references.citation: Science. 2011 Dec 16;334(6062):1561-5
references.pmid: 22033518
references.citation: Toxicol Sci. 2011 Sep;123(1):26-36
references.pmid: 21666223
references.citation: Mol Pharmacol. 2012 Mar;81(3):338-47
references.pmid: 22113079
references.citation: Toxicol Appl Pharmacol. 2008 Mar 1;227(2):196-206
references.pmid: 18048071
references.citation: J Biol Chem. 2009 Jan 30;284(5):2690-6
references.pmid: 19054769
references.citation: Environ Toxicol Pharmacol. 1997 Jul;3(3):211-20
references.pmid: 21781780
references.citation: J Agric Food Chem. 2003 Aug 27;51(18):5478-87
references.pmid: 12926901
references.citation: Toxicol Sci. 2010 May;115(1):89-97
references.pmid: 20106948
references.citation: Biochem Pharmacol. 1989 Jul 15;38(14 ):2339-48
references.pmid: 2546564
references.citation: Toxicol Sci. 2011 Nov;124(1):1-22
references.pmid: 21908767
references.citation: J Biol Chem. 1976 Aug 25;251(16):4936-46
references.pmid: 956169
references.citation: Toxicol Sci. 2011 Mar;120(1):68-78
references.pmid: 21131560
references.citation: Mol Pharmacol. 2006 Jun;69(6):1871-8
references.pmid: 16540597
references.citation: Dig Dis Sci. 2011 Sep;56(9):2532-44
references.pmid: 21374063
references.citation: Mol Endocrinol. 2009 Apr;23 (4):549-58
references.pmid: 19147701
references.citation: Toxicol Sci. 2005 Jun;85(2):935-43
references.pmid: 15788723